[go: up one dir, main page]

NO20065502L - Farmasoytiske sammensetninger. - Google Patents

Farmasoytiske sammensetninger.

Info

Publication number
NO20065502L
NO20065502L NO20065502A NO20065502A NO20065502L NO 20065502 L NO20065502 L NO 20065502L NO 20065502 A NO20065502 A NO 20065502A NO 20065502 A NO20065502 A NO 20065502A NO 20065502 L NO20065502 L NO 20065502L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
relates
present
glycopyrrolate
antimuscarinic
Prior art date
Application number
NO20065502A
Other languages
English (en)
Inventor
David Morton
Martin Shott
Rebecca Davies
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065502(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of NO20065502L publication Critical patent/NO20065502L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår farmasøytiske preparater omfattende det antimuskarine middel glykopyrrolat, for eksempel saltet glykopyrroniumbromid. Spesielt angår foreliggende oppfinnelse tørrpulver-preparater som viser forbedret stabilitet over tid og metoder for å produsere disse.
NO20065502A 2004-04-30 2006-11-29 Farmasoytiske sammensetninger. NO20065502L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20065502L true NO20065502L (no) 2007-01-24

Family

ID=32408337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065502A NO20065502L (no) 2004-04-30 2006-11-29 Farmasoytiske sammensetninger.

Country Status (26)

Country Link
US (1) US20080063719A1 (no)
EP (3) EP1755555B1 (no)
JP (2) JP5000483B2 (no)
KR (1) KR101287919B1 (no)
CN (3) CN1964700A (no)
AU (2) AU2005237266B2 (no)
BR (1) BRPI0510500B8 (no)
CA (1) CA2563760C (no)
CY (6) CY1113069T1 (no)
DK (2) DK2422766T3 (no)
ES (2) ES2546982T3 (no)
GB (1) GB0409703D0 (no)
HU (4) HUE025463T2 (no)
IL (2) IL178651A (no)
LT (1) LTC2422766I2 (no)
LU (2) LU92176I2 (no)
MX (2) MXPA06012493A (no)
NO (1) NO20065502L (no)
NZ (1) NZ550479A (no)
PL (2) PL2422766T3 (no)
PT (2) PT1755555E (no)
RU (1) RU2396943C2 (no)
SG (3) SG186673A1 (no)
SI (2) SI2422766T1 (no)
WO (1) WO2005105043A2 (no)
ZA (1) ZA200609350B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
RU2496479C2 (ru) * 2007-12-13 2013-10-27 Новартис Аг Органические соединения
PT2234595E (pt) * 2007-12-13 2013-01-24 Novartis Ag Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
CN102458372A (zh) * 2009-04-24 2012-05-16 先灵公司 适用在干粉吸入器中的聚结物制剂
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
BR112012023407A2 (pt) * 2010-03-31 2019-09-24 Glenmark Pharmaceuticals Ltd composição em pó farmacêutica para instalação, e, processo para a preparação da mesma.
BR112012024059B1 (pt) * 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
KR20130062268A (ko) * 2010-04-21 2013-06-12 키에시 파르마슈티시 엣스. 피. 에이. 정전하가 감소된 입자를 제공하는 방법
EP2611423B2 (en) 2010-08-31 2022-09-21 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
ES2705494T3 (es) 2010-08-31 2019-03-25 Glaxosmithkline Ip Dev Ltd Productos farmacológicos para la inhalación de polvo seco que presentan propiedades de control de la humedad y procedimientos de administración de los mismos
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
ES2793905T3 (es) * 2014-09-09 2020-11-17 Vectura Ltd Formulación que comprende glicopirrolato, método y aparato
JP6653324B2 (ja) * 2014-10-16 2020-02-26 テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド 乾燥粉末製剤
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
MX385717B (es) 2016-03-08 2025-03-18 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de enfermedad pulmonar obstructiva cronica.
MX389563B (es) 2016-03-08 2025-03-20 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
PL3490533T3 (pl) 2016-07-29 2020-11-02 Inke, S.A. Sposób stabilizacji rozmiaru cząstek
PE20191043A1 (es) 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
ES3009923T3 (en) 2017-03-15 2025-03-31 Vectura Ltd Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
DK3585383T3 (da) 2017-12-11 2021-04-19 Mereo Biopharma 1 Ltd Anvendelse af 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamid i forebyggelsen af akutte forværringer af kronisk obstruktiv lungesygdom
US11701341B2 (en) 2017-12-11 2023-07-18 Mereo Biopharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
DK1131059T3 (da) * 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
DK2283818T3 (en) 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
KR20050003416A (ko) * 2002-05-07 2005-01-10 넥타르 테라퓨틱스 건조분말 흡입기용 캡슐 및 이의 제조 및 사용 방법
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
JP2008534480A (ja) * 2005-03-24 2008-08-28 ソーセイ アールアンドディ リミテッド グリコピロニウム塩およびそれらの治療的使用

Also Published As

Publication number Publication date
AU2005237266B2 (en) 2010-11-11
PL2422766T3 (pl) 2015-11-30
AU2011200543A1 (en) 2011-03-03
EP1755555A2 (en) 2007-02-28
DK1755555T3 (da) 2012-08-20
EP1755555B1 (en) 2012-05-23
CN107252423A (zh) 2017-10-17
IL223545A (en) 2016-04-21
IL178651A (en) 2012-12-31
JP5124718B2 (ja) 2013-01-23
EP2422766B1 (en) 2015-06-24
IL178651A0 (en) 2007-02-11
CA2563760C (en) 2013-07-02
HUE025463T2 (en) 2016-02-29
CY1113069T1 (el) 2015-08-05
HK1095282A1 (en) 2007-05-04
DK2422766T3 (da) 2015-08-31
AU2011200543A8 (en) 2011-03-31
CN102008453A (zh) 2011-04-13
SG186673A1 (en) 2013-01-30
HK1167334A1 (en) 2012-11-30
RU2396943C2 (ru) 2010-08-20
CY2014015I1 (el) 2015-12-09
LU92392I2 (fr) 2015-11-02
SG152292A1 (en) 2009-05-29
EP2422767A2 (en) 2012-02-29
NZ550479A (en) 2009-11-27
EP2422767A3 (en) 2012-04-25
HUS1300006I1 (hu) 2016-07-28
PT1755555E (pt) 2012-08-17
LU92176I2 (fr) 2013-05-27
PT2422766E (pt) 2015-10-12
MXPA06012493A (es) 2007-01-29
CA2563760A1 (en) 2005-11-10
BRPI0510500B1 (pt) 2019-04-24
ES2388289T3 (es) 2012-10-11
JP2012031209A (ja) 2012-02-16
SI2422766T1 (sl) 2015-10-30
WO2005105043A3 (en) 2006-05-04
IL223545A0 (en) 2013-02-03
HUS1500072I1 (hu) 2016-02-29
EP2422766A3 (en) 2012-04-25
AU2005237266A1 (en) 2005-11-10
CY1116655T1 (el) 2017-03-15
CY2013012I1 (el) 2015-08-05
AU2011200543B2 (en) 2012-11-29
CY2015059I1 (el) 2020-05-29
KR20070033978A (ko) 2007-03-27
LU92176I9 (no) 2019-01-04
ES2546982T3 (es) 2015-09-30
CN1964700A (zh) 2007-05-16
SG10201605001SA (en) 2016-08-30
WO2005105043A2 (en) 2005-11-10
ZA200609350B (en) 2008-04-30
KR101287919B1 (ko) 2013-07-18
EP2422766A2 (en) 2012-02-29
US20080063719A1 (en) 2008-03-13
JP2007535522A (ja) 2007-12-06
CY2014015I2 (el) 2015-12-09
RU2006142322A (ru) 2008-06-20
LTC2422766I2 (lt) 2020-02-10
BRPI0510500B8 (pt) 2021-05-25
HUS1500073I1 (hu) 2016-02-29
CY2015060I1 (el) 2020-05-29
PL1755555T3 (pl) 2012-11-30
BRPI0510500A (pt) 2007-10-30
GB0409703D0 (en) 2004-06-02
JP5000483B2 (ja) 2012-08-15
SI1755555T1 (sl) 2012-10-30
CY2013012I2 (el) 2015-08-05
MX341426B (es) 2016-08-18

Similar Documents

Publication Publication Date Title
NO20065502L (no) Farmasoytiske sammensetninger.
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20076046L (no) Bindemidler
IL187311A0 (en) N,n-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
NO20071823L (no) Testosterongeler omfattende polypropylenglykol som gjennomtrengningsforsterker
EA200702347A1 (ru) Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения
DE602004010164D1 (de) Capsaicinderivate und deren produktion und verwendung
IL190730A0 (en) Potassium channel inhibitors
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
TW200716622A (en) Substituted piperidines
EA200801414A1 (ru) Кальцилитические соединения
NO20055830D0 (no) Proglitazpnsalter, sa som pioglitazonsulfat og farmasoytiske sammensetnnger og fremgangsmater ved bruk av de samme
WO2006079057A3 (en) Methods and compositions for specific inhibition of protein splicing by small molecules
DK1594868T3 (da) 8-aza-bicyclo[3.2.1]octanderivater og anvendelse deraf som monoamin-neurotransmitter-genoptagelsesinhibitorer
DE602005023528D1 (de) Piperidinderivate als prodrugs von kaliumkanalinhibitoren
NO20080409L (no) Fremgangsmater og preparater til malsoking av IFNAR2
WO2005120200A3 (en) Amine compounds and inhibiting neurotransmitter reuptake
ITMI20040146A1 (it) Ibopamina maleato metodo per prepararlo e composizioni farmaceutiche che lo comprendono

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application